MARKET

CYCCP

CYCCP

Cyclacel Phar Pr
NASDAQ
6.99
+0.29
+4.33%
After Hours: 6.53 -0.46 -6.58% 16:00 05/20 EDT
OPEN
6.50
PREV CLOSE
6.70
HIGH
6.99
LOW
6.50
VOLUME
1.45K
TURNOVER
0
52 WEEK HIGH
22.20
52 WEEK LOW
5.25
MARKET CAP
2.34M
P/E (TTM)
-0.2613
1D
5D
1M
3M
1Y
5Y
Cyclacel Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 6d ago
Weekly Report: what happened at CYCCP last week (0506-0510)?
Weekly Report · 05/13 09:40
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. Will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The biopharmaceutical company developing innovative medicines based on cancer cell biology. The Company will host a conference call and live webcast on the same day.
Barchart · 05/08 08:15
BRIEF-Cyclacel Pharmaceuticals Inc Files For Resale Of Up To 15.2 Million Shares By The Selling Stockholders
Cyclacel Pharmaceuticals Inc files for resale of up to 15.2 million shares by the selling stockholders. The company says the shares will be sold by the Selling Stockholders. Cyclacel is a maker of drugs for cancer and other diseases. The shares are traded on the New York Stock Exchange.
Reuters · 05/06 21:29
CYCLACEL PHARMACEUTICALS INC FILES FOR RESALE OF UP TO 15.2 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/06 21:28
Weekly Report: what happened at CYCCP last week (0429-0503)?
Weekly Report · 05/06 09:42
CYCLACEL PHARMACEUTICALS ANNOUNCES CLOSING OF $8.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 05/02 20:30
CYCLACEL PHARMACEUTICALS ANNOUNCES $8.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 04/30 11:00
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.